A rare case of extraluminal gastrointestinal stromal tumor of the ileum presenting with lower urinary tract symptoms

A case report

Chung-Hao Yu, MD, Hui-Kung Ting, MD, Chien-Chang Kao, MD, Wen-Chuan Tsai, MD, Sheng-Tang Wu, MD, Dah-Shyong Yu, MD, PhD

Abstract

Introduction: Benign prostatic hyperplasia, bladder outlet obstruction, and overactive bladder are major causes of lower urinary tract symptoms (LUTS). Tumor compression of the urinary bladder resulting in LUTS was clinically observed. Gastrointestinal stromal tumors (GISTs) presenting with LUTS have not been reported before. Herein, we report a patient with extraluminal GIST of the ileum who had LUTS without gastrointestinal symptoms during the clinical course.

Patient concerns: A 68-year-old man visited the genitourinary outpatient department because of frequent urination with mild dysuria. He also complained of poor appetite, fatigue, and body weight loss of 10 kg over 6 months. A large presacral solid mass lesion compressing the bladder and surrounded by the bowel with gas content was identified through abdominal computed tomography.

Diagnosis: GIST of the ileum with mesenteric invasion was revealed by pathological examination.

Interventions: Exploratory laparotomy with removal of the pelvic tumor and segmental resection of the ileum was performed.

Outcomes: Now, he received adjuvant imatinib target therapy for 1 year with stable condition.

Conclusion: Extravesical compression or invasion of the urinary bladder by a pelvic mass lesion is common but is rarely accompanied by GISTs of the ileum. Specific findings identified through imaging should alert the surgeon to this specific entity and prepare thoroughly before surgical intervention.

Abbreviations: BOO = bladder outlet obstruction, BPH = benign prostatic hyperplasia, CT = computed tomography, GISTs = gastrointestinal stromal tumors, LUTS = lower urinary tract symptoms, MRI = magnetic resonance imaging.

Keywords: differential diagnosis, gastrointestinal stromal tumors, LUTS

1. Introduction

Lower urinary tract symptoms (LUTS) generally refer to a combination of urinary symptoms, such as frequency, urgency, and nocturia, relating to storage or voiding disturbances common among older men. Benign prostatic hyperplasia and bladder outlet obstruction are the common causes of LUTS.[1]

During the 1990s, nonepithelial tumors of the gastrointestinal tract were called “gastrointestinal stromal tumors” (GISTs). They originate from the interstitial cells of Cajal and constitute less than 1% of all gastrointestinal tumors. GISTs are most commonly located in the stomach (40%–60%) and jejunum/ileum (25%–30%). The duodenum (5%), colorectum (5%–15%), and esophagus (<1%) are less common sites.[2–5]

Up to 75% of GISTs are discovered when they are less than 4 cm in diameter and are either asymptomatic or associated with nonspecific symptoms. Patients may complain of nonspecific abdominal pain or discomfort, a sensation of abdominal fullness, palpable abdominal mass, malaise, fatigue, or exertional dyspnea with significant blood loss or focal or widespread signs of peritonitis due to perforation.[2–5]

2. Case report

2.1. Patient information

This report presents a 68-year-old man who initially had experienced poor appetite, fatigue, occasional mild lower abdominal discomfort, and body weight loss of 10 kg over 6 months but no nausea, vomiting, diarrhea, or tarry or bloody...
stool symptoms occurred. Afterward, he noticed frequent urination with mild dysuria. Therefore, he visited the outpatient department for further management in our hospital. Cystoscopy was performed, and the findings were normal in addition to external compression of dome and posterior wall of bladder was seen. Abdominal sonography revealed a solid mass nearby the bladder. Computed tomography (CT) of the abdomen revealed a large, presacral, solid mass lesion (13 × 11 × 9 cm) with gas content, locating posteriorly to the urinary bladder (arrow).

2.2. Surgical and pathological findings

Exploratory laparotomy with removal of the pelvic tumor and segmental resection of the ileum was performed. A fistula tract from the ileum lumen into tumor was seen in the specimen (Fig. 2). No severe adhesion with easy division between the tumor mass and bladder were observed during operation. The pathological examination revealed that the tumor had invaded the submucosa and muscle layer of the ileum and mesentery (Fig. 3). Dog-1 and CD117 staining were positive according to the immunohistochemistry report. An exophytic GIST of the ileum with fistula formation and mesenteric invasion, pT4N0M0, stage III-B was diagnosed.

2.3. Follow-up and outcomes

The patient was referred to the oncology department for 1-year adjuvant imatinib targeted therapy and no tumor recurrence has been noted to date.

3. Discussion

Some abdominal masses may compress against the urinary bladder and lead to secondary LUTS, including uterine and rectal masses. Nevertheless, some case reports have revealed that extrabowel GISTs of the prostate and urinary bladder are associated with urinary tract symptoms.[2–5] However, no patients with GISTs in the ileum with urinary bladder compression and LUTS occurred had been reported.

In such cases, intravenous urography, cystoscopy, or urine cytology can be performed initially; subsequently, CT or MRI may be considered, since GIST screening and staging must be performed through CT or MRI.[6,7] Fluorodeoxyglucose positron emission tomography (PET) is highly sensitive at detecting GISTs and their metastases, since patients with LUTS but no signs of gastrointestinal obstruction are frequently misdiagnosed.

Preoperative biopsy is not usually recommended for resectable lesions that display a high suspicion of GISTs.[7] Primary tumor resection should be performed through standard management and the diagnosis should be confirmed by pathology. Complete resection is possible in most cases of localized GISTs; however, only approximately half of cases remain recurrence free for 5 years or more with surgery alone.
Approximately, 80% of GISTs have a mutation of the KIT protooncogene, a member of the receptor tyrosine kinase family[8–11] and CD117 and Dog-1 are highly specific for GIST.[12]

The GISTs were treated using adjuvant and neoadjuvant small molecule tyrosine kinase inhibitors such as imatinib. Following imatinib introduction, the median survival of patients with advanced GIST was 60 months.[13,14] In this study, the patient underwent imatinib treatment for 1 year without complications. LUTS occurred by ileal GIST tumor compression of bladder is very rare. Clinicians should keep in mind the possible existence of GIST and select appropriate procedures or imaging for diagnosis and proper treatment.

Author contributions
Conceptualization: Sheng-Tang Wu.
Data curation: Hui-Kung Ting, Chien-Chang Kao, Wen-Chiuan Tsai.
Supervision: Sheng-Tang Wu.
Writing – original draft: Chung-Hao Yu, Daz-Shyong Yu.
Writing – review & editing: Chung-Hao Yu.

References
[1] Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779–87.
[2] Chen Y-C, Tsai J-W, Chen H-P, et al. Retroperitoneal extragastrointestinal stromal tumor presenting with lower urinary tract symptoms. Urol Sci 2010;21:148–51.
[3] Van der Aa F, Sciot R, Blyweert W, et al. Gastrointestinal stromal tumor of the prostate. Urology 2005;65:388.
[4] Agaimy A, Wünsch PH. Gastrointestinal stromal tumors: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra gastrointestinal stromal tumors. Langenbecks Arch Surg 2006;391:322–9.
[5] Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000;13:577–85.
[6] Takao H, Yamahira K, Doi I, et al. Gastrointestinal stromal tumor of the retroperitoneum: CT and MR findings. Eur Radiol 2004;14:1926–9.
[7] Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:439–65.
[8] Yamamoto H, Oda Y, Kawaguchi K, et al. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue). Am J Surg Pathol 2004;28:479–88.
[9] Mazur MT, Clark HK. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507–19.
[10] Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 1996;119:171–7.
[11] Lasota J, Carlson JA, Miettinen M. Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor. Arch Pathol Lab Med 2000;124:894–7.
[12] Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33:1401–8.
[13] Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–38.
[14] Iesalnieks I, Rümmele P, Dietmaier W, et al. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 2005;124:740–8.